Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans

@article{Vermeir2008AbsorptionMA,
  title={Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans},
  author={Marc Vermeir and Ineke Naessens and Bart Remmerie and G. S. J. Mannens and Jan F. A. Hendrickx and Patrick Sterkens and K. Talluri and Sandra P. A. Boom and Mari{\"e}lle Eerdekens and Nancy van Osselaer and Adriaan Cleton},
  journal={Drug Metabolism and Disposition},
  year={2008},
  volume={36},
  pages={769 - 779}
}
Absorption, metabolism, and excretion of paliperidone, an atypical antipsychotic, was studied in five healthy male subjects after a single dose of 1 mg of [14C]paliperidone oral solution (∼16 μCi/subject). One week after dosing, 88.4 to 93.8% (mean 91.1%) of the administered radioactivity was excreted: 77.1 to 87.1% (mean 79.6%) in urine and 6.8 to 14.4% (mean 11.4%) in the feces. Paliperidone was the major circulating compound (97% of the area under the plasma concentration-time curve at 24 h… 

Figures and Tables from this paper

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.

Paliperidone's disposition after oral administration was characterized by a one-compartment pharmacokinetic model and results obtained in Chinese subjects were similar to those obtained in Japanese and Caucasian subjects.

Safety and Multiple Dose Pharmacokinetics of Paliperidone ER In Indian Schizophrenic Patients.

Paliperidone ER was very well tolerated during the pharmacokinetics study and was well tolerated in patients who continued the medication after completion of phase III clinical trial.

Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation

The data show a 4-fold interindividual difference in dose-adjusted serum concentrations within the 10–90 percentile range and illustrate the significant effects of age and p-glycoprotein induction on the pharmacokinetics of paliperidone.

The pharmacokinetics of paliperidone versus risperidone.

Clinicians can use R/9-OHR and the C/D ratios to interpret plasma R levels and guide treatment and suggest the major route of paliperidone elimination.

Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone.

The active metabolite has dopamine D2 receptor affinity similar to that of the parent compound, but has a longer half-life of approximately 24 hours, and is thus present in higher concentrations and exerts most of the pharmacological effect when risperidone is administered orally.

Interaction Between Paliperidone and Carbamazepine

It is suggested that adjunctive treatment with carbamazepine reduces the concentration of paliperidone in a dose-dependent manner, most likely because of the induction of several drug-metabolizing enzymes and several drug transporters.

The pharmacology and formulation of paliperidone extended release

The ER formulation of paliperidone results in decreased fluctuations in plasma drug levels and allows for once-daily administration with initial tolerability that permits treatment initiation at a clinically effective dose without the need for titration, leading to potentially better adherence and improved outcome.

Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability

  • L. Citrome
  • Medicine, Psychology
    Expert opinion on drug metabolism & toxicology
  • 2012
The pharmacokinetic profile of paliperidone and its clinical implications in the treatment of schizophrenia and schizoaffective disorder are described and the use of palipersidone ER will need to be considered within the context of its cost and availability.

Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in Taiwan

Under the suggested DD for oral and LAI paliperidone treatment, most Taiwanese patients with schizophrenia can reach the suggested therapeutic Cps range.

Pharmacokinetics of felbinac after intravenous administration of felbinac trometamol in rats

It would appear that felbinac trometamol has the potential to replace lipid-based NSAID formulations and progress to clinical evaluation.
...

References

SHOWING 1-10 OF 19 REFERENCES

Absorption, metabolism, and excretion of risperidone in humans.

The absorption, metabolism, and excretion of the novel antipsychotic risperidone was studied in three healthy male subjects and the pharmacokinetics of the active fraction remained similar among the three subjects.

Plasma protein binding of risperidone and its distribution in blood

The plasma protein binding of ris peridone and 9-hydroxy-risperidone in the elderly was not significantly different from that in young subjects and the protein binding differences between patients with hepatic or renal impairment and healthy subjects were either not significant or rather small.

Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Risperidone and its active metabolite 9-OH-risperidone were compared to reference antipsychotic drugs (haloperidol, pipamperone, fluspirilene, clozapine, zotepine) and compounds under development

In vivo pharmacological profile of 9‐hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone

As metabolic conversion of risperidone to 9OH‐risperidones does apparently not result in any marked change in activity profile, its major consequence seems to be a prolongation of duration of action.

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

The formation of 9-Hydroxyrisperidone is highly correlated with testosterone 6β-hydroxylase activities, suggesting that inducible CYP3A contributes significantly to the metabolism of ris peridone in rat.

Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study

Paliperidone Extended Release

Paliperidone ER 3–12 mg/day for 6 weeks was generally well tolerated by patients with schizophrenia in clinical trials and demonstrated superior efficacy to placebo in preventing the recurrence of schizophrenia symptoms.

Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.